S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Closing prices for crude oil, gold and other commodities
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
2 Important Retail Stock Battles to Watch
Pipeline break spills 45,000 gallons of diesel in Wyoming
Sinema took Wall Street money while killing tax on investors
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
MarketBeat: Week in Review 8/8 - 8/12
Expanded IRS free-file system one step closer in Dems' bill
In Biden's big bill: Climate, health care, deficit reduction
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Closing prices for crude oil, gold and other commodities
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
2 Important Retail Stock Battles to Watch
Pipeline break spills 45,000 gallons of diesel in Wyoming
Sinema took Wall Street money while killing tax on investors
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
MarketBeat: Week in Review 8/8 - 8/12
Expanded IRS free-file system one step closer in Dems' bill
In Biden's big bill: Climate, health care, deficit reduction
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Closing prices for crude oil, gold and other commodities
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
2 Important Retail Stock Battles to Watch
Pipeline break spills 45,000 gallons of diesel in Wyoming
Sinema took Wall Street money while killing tax on investors
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
MarketBeat: Week in Review 8/8 - 8/12
Expanded IRS free-file system one step closer in Dems' bill
In Biden's big bill: Climate, health care, deficit reduction
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Closing prices for crude oil, gold and other commodities
Biden & Bill Gates Igniting $40 Trillion Heist? (Ad)
2 Important Retail Stock Battles to Watch
Pipeline break spills 45,000 gallons of diesel in Wyoming
Sinema took Wall Street money while killing tax on investors
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
MarketBeat: Week in Review 8/8 - 8/12
Expanded IRS free-file system one step closer in Dems' bill
In Biden's big bill: Climate, health care, deficit reduction
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
NASDAQ:XBIO

Xenetic Biosciences - XBIO Stock Forecast, Price & News

$0.92
+0.04 (+4.53%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.89
$0.93
50-Day Range
$0.66
$0.94
52-Week Range
$0.45
$3.67
Volume
17,257 shs
Average Volume
63,301 shs
Market Capitalization
$13.21 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

Xenetic Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
333.7% Upside
$4.00 Price Target
Short Interest
Healthy
2.29% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.49mentions of Xenetic Biosciences in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.46) to ($0.38) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.40 out of 5 stars

Medical Sector

309th out of 1,117 stocks

Pharmaceutical Preparations Industry

150th out of 550 stocks

XBIO stock logo

About Xenetic Biosciences (NASDAQ:XBIO) Stock

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

Xenetic Biosciences Trading Up 4.8 %

NASDAQ:XBIO traded up $0.04 during trading hours on Friday, reaching $0.92. 17,257 shares of the stock were exchanged, compared to its average volume of 130,420. The firm has a 50 day simple moving average of $0.81 and a 200-day simple moving average of $0.88. Xenetic Biosciences has a 52 week low of $0.45 and a 52 week high of $3.67.

Xenetic Biosciences (NASDAQ:XBIO - Get Rating) last announced its quarterly earnings results on Thursday, May 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.01). The company had revenue of $0.39 million during the quarter, compared to the consensus estimate of $0.34 million. Xenetic Biosciences had a negative return on equity of 36.03% and a negative net margin of 433.70%. On average, analysts predict that Xenetic Biosciences will post -0.46 EPS for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reduced their target price on Xenetic Biosciences from $5.00 to $4.00 in a report on Monday, May 2nd.

Receive XBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xenetic Biosciences and its competitors with MarketBeat's FREE daily newsletter.

XBIO Stock News Headlines

Xenetic Biosciences reports Q1 results
15 Best High Volume Stocks to Buy Now
See More Headlines
Receive XBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Xenetic Biosciences and its competitors with MarketBeat's FREE daily newsletter.

XBIO Company Calendar

Last Earnings
11/11/2021
Today
8/13/2022
Next Earnings (Estimated)
11/11/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:XBIO
Fax
N/A
Employees
4
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.00
High Stock Price Forecast
$4.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+333.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-5,640,000.00
Net Margins
-433.70%
Pretax Margin
-433.70%

Debt

Sales & Book Value

Annual Sales
$1.16 million
Book Value
$1.37 per share

Miscellaneous

Free Float
13,658,000
Market Cap
$13.21 million
Optionable
Not Optionable
Beta
2.32














XBIO Stock - Frequently Asked Questions

Should I buy or sell Xenetic Biosciences stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Xenetic Biosciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" XBIO shares.
View XBIO analyst ratings
or view top-rated stocks.

What is Xenetic Biosciences' stock price forecast for 2022?

1 Wall Street analysts have issued twelve-month price objectives for Xenetic Biosciences' shares. Their XBIO share price forecasts range from $4.00 to $4.00. On average, they expect the company's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 333.7% from the stock's current price.
View analysts price targets for XBIO
or view top-rated stocks among Wall Street analysts.

How have XBIO shares performed in 2022?

Xenetic Biosciences' stock was trading at $1.29 at the beginning of 2022. Since then, XBIO stock has decreased by 28.5% and is now trading at $0.9222.
View the best growth stocks for 2022 here
.

How were Xenetic Biosciences' earnings last quarter?

Xenetic Biosciences Inc (NASDAQ:XBIO) issued its quarterly earnings data on Thursday, November, 11th. The company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by $0.01. The business earned $0.35 million during the quarter, compared to the consensus estimate of $0.20 million. Xenetic Biosciences had a negative trailing twelve-month return on equity of 36.03% and a negative net margin of 433.70%.

What other stocks do shareholders of Xenetic Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Xenetic Biosciences investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Biocept (BIOC), Trevena (TRVN), TherapeuticsMD (TXMD), T2 Biosystems (TTOO), Vaxart (VXRT), Aytu BioPharma (AYTU) and Co-Diagnostics (CODX).

What is Xenetic Biosciences' stock symbol?

Xenetic Biosciences trades on the NASDAQ under the ticker symbol "XBIO."

Who are Xenetic Biosciences' major shareholders?

Xenetic Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (1.06%).

How do I buy shares of Xenetic Biosciences?

Shares of XBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Xenetic Biosciences' stock price today?

One share of XBIO stock can currently be purchased for approximately $0.92.

How much money does Xenetic Biosciences make?

Xenetic Biosciences (NASDAQ:XBIO) has a market capitalization of $13.20 million and generates $1.16 million in revenue each year.

How can I contact Xenetic Biosciences?

Xenetic Biosciences' mailing address is 40 Speen Street Suite 102, Framingham MA, 01701. The official website for the company is www.xeneticbio.com. The company can be reached via phone at 781-778-7720 or via email at xbio@jtcir.com.

This page (NASDAQ:XBIO) was last updated on 8/13/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.